| |
Latest 10 SEC filings (by transaction date) for MDGL within the last 6 months | [?] |
Amended Filing Footnote and/or Remark |
Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
---|---|---|---|---|---|---|---|
Apr 10/24 | Apr 8/24 | Taub Rebecca | Direct Ownership | Stock Option (Right to Buy) | M - Exercise or conversion exempt under rule 16b-3 | -2,676 | |
Apr 10/24 | Apr 8/24 | Taub Rebecca | Direct Ownership | Common Stock | S - Open market or private sale | -200 | $248.58 |
Apr 10/24 | Apr 8/24 | Taub Rebecca | Direct Ownership | Common Stock | S - Open market or private sale | -407 | $247.76 |
Apr 10/24 | Apr 8/24 | Taub Rebecca | Direct Ownership | Common Stock | S - Open market or private sale | -600 | $246.98 |
Apr 10/24 | Apr 8/24 | Taub Rebecca | Direct Ownership | Common Stock | S - Open market or private sale | -300 | $245.69 |
Apr 10/24 | Apr 8/24 | Taub Rebecca | Direct Ownership | Common Stock | S - Open market or private sale | -945 | $244.79 |
Apr 10/24 | Apr 8/24 | Taub Rebecca | Direct Ownership | Common Stock | S - Open market or private sale | -224 | $243.25 |
Apr 10/24 | Apr 8/24 | Taub Rebecca | Direct Ownership | Common Stock | M - Exercise or conversion exempt under rule 16b-3 | 2,676 | $9.45 |
Apr 10/24 | Apr 8/24 | Friedman Paul A | Direct Ownership | Common Stock | S - Open market or private sale | -4,866 | $248.59 |
Apr 10/24 | Apr 8/24 | Friedman Paul A | Direct Ownership | Common Stock | S - Open market or private sale | -3,464 | $247.76 |
Sign up or login above to see all SEC filings within the past 6 months. |
Latest 10 SEC filings (by filing date) for MDGL within the last 6 months | [?] |
Amended Filing Footnote and/or Remark |
Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
---|---|---|---|---|---|---|---|
Apr 10/24 | Apr 8/24 | Taub Rebecca | Direct Ownership | Stock Option (Right to Buy) | M - Exercise or conversion exempt under rule 16b-3 | -2,676 | |
Apr 10/24 | Apr 8/24 | Taub Rebecca | Direct Ownership | Common Stock | S - Open market or private sale | -200 | $248.58 |
Apr 10/24 | Apr 8/24 | Taub Rebecca | Direct Ownership | Common Stock | S - Open market or private sale | -407 | $247.76 |
Apr 10/24 | Apr 8/24 | Taub Rebecca | Direct Ownership | Common Stock | S - Open market or private sale | -600 | $246.98 |
Apr 10/24 | Apr 8/24 | Taub Rebecca | Direct Ownership | Common Stock | S - Open market or private sale | -300 | $245.69 |
Apr 10/24 | Apr 8/24 | Taub Rebecca | Direct Ownership | Common Stock | S - Open market or private sale | -945 | $244.79 |
Apr 10/24 | Apr 8/24 | Taub Rebecca | Direct Ownership | Common Stock | S - Open market or private sale | -224 | $243.25 |
Apr 10/24 | Apr 8/24 | Taub Rebecca | Direct Ownership | Common Stock | M - Exercise or conversion exempt under rule 16b-3 | 2,676 | $9.45 |
Apr 10/24 | Apr 8/24 | Friedman Paul A | Direct Ownership | Common Stock | S - Open market or private sale | -4,866 | $248.59 |
Apr 10/24 | Apr 8/24 | Friedman Paul A | Direct Ownership | Common Stock | S - Open market or private sale | -3,464 | $247.76 |
Sign up or login above to see all SEC filings within the past 6 months. |
Sign up or login above to see the past 6 months of filings sorted by insider. . |
Competitors with Recent Insider Filings |
Neurocrine Biosciences (OQ:NBIX) |
Regeneron Pharmaceuticals (OQ:REGN) |
Vertex Pharmaceuticals (OQ:VRTX) |